---
document_datetime: 2023-09-21 19:01:39
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/conbriza-epar-all-authorised-presentations_en.pdf
document_name: conbriza-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.022183
conversion_datetime: 2025-12-19 22:56:47.1819
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| EU Procedure number   | Invented name   | Strength   | Pharmaceutical Form   | Route of administration   | Packaging           | Package size   |
|-----------------------|-----------------|------------|-----------------------|---------------------------|---------------------|----------------|
| EU/1/09/511/001       | CONBRIZA        | 20 mg      | Film-coated tablet    | Oral use                  | Blister (PVC/Aclar) | 28 tablets     |
| EU/1/09/511/002       | CONBRIZA        | 20 mg      | Film-coated tablet    | Oral use                  | Blister (PVC/Aclar) | 30 tablets     |
| EU/1/09/511/003       | CONBRIZA        | 20 mg      | Film-coated tablet    | Oral use                  | Blister (PVC/Aclar) | 84 tablets     |
| EU/1/09/511/004       | CONBRIZA        | 20 mg      | Film-coated tablet    | Oral use                  | Blister (PVC/Aclar) | 90 tablets     |
| EU/1/09/511/005       | CONBRIZA        | 20 mg      | Film-coated tablet    | Oral use                  | Blister (PVC/Aclar) | 7 tablets      |